New drug launched by Beacon for Rheumatic arthritis.

BEACON introduces another promising kinase inhibitor, Baricitinib, under the brand name of Baricinix  for global market.

Baricinix is an anti-rheumatic drug. It is used in-

• The treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to or who are intolerant to one or more disease odifying anti rheumatic drugs.

• Baricitinib may be used as monotherapy or in combination with Methotrexate.

• Baricinix is an oral tablet preparation which is available in the strengths of 2 mg and 4 mg.

To know more visit our product website : www.baricinix.com